There is a robust pipeline of potential therapies for Huntington’s disease (HD), which I’ve discussed in previous columns. All of the current and future clinical trials provide real hope for this community. However, people typically aren’t allowed to participate in two clinical trials at the same time, and down the line, they likely won’t be able to take an approved medication while simultaneously participating in a clinical trial. That leads to a dilemma for the…

You must be logged in to read/download the full post.